OpenAI acquires Orchestra Bio for Rosalind drug operations

OpenAI has acquired Orchestra Bio to expand its life-sciences suite, Rosalind, into the operational workflows of drug development. Orchestra's AI agents coordinate studies, vendors, and timelines to help biopharmaceutical teams manage the complex process between scientific discovery and approved treatments. Terms of the transaction were not disclosed. Open article →